Cargando…
Comorbidity Burden in Patients with Covid-19 Treated with Molnupiravir in the United States
Individuals with certain medical conditions, e.g., diabetes, heart, and/or lung disease, are at higher risk of severe COVID-19. Molnupiravir, an oral antiviral drug for treatment of mild-to-moderate COVID-19 in certain adults, was granted US FDA emergency use authorization. Retrospective analyses of...
Autores principales: | Prajapati, Girish, Das, Amar, Sun, Yezhou, Fonseca, Eileen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Mosby, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723265/ http://dx.doi.org/10.1016/j.ahj.2022.10.034 |
Ejemplares similares
-
Molnupiravir for COVID-19
Publicado: (2022) -
NZ's Pharmac negotiates deal for molnupiravir to treat COVID-19
Publicado: (2021) -
The burden of acute pancreatitis on COVID-19 in the United States
por: Chaudhry, Hunza, et al.
Publicado: (2023) -
Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
por: Bai, Yuan, et al.
Publicado: (2022) -
Efficacy and safety of molnupiravir for COVID-19 patients
por: Fatima, Maurish, et al.
Publicado: (2022)